Danaher Corp. announced Tuesday it will acquire Masimo Corp. in a blockbuster $9.9 billion transaction, including debt, a move set to reshape the global diagnostics landscape. Kirkland & Ellis LLP is advising Danaher, while Sullivan & Cromwell LLP and White & Case LLP represent Masimo.
Cash Deal and Strategic Integration
Under the agreement, Danaher will pay $180 per share in cash for all outstanding Masimo common stock. After the deal closes, Masimo is expected to operate as a standalone unit within Danaher’s diagnostics segment, alongside established units such as Radiometer, Leica Biosystems, Cepheid, and Beckman Coulter Diagnostics.
Danaher CEO and President Rainer M. Blair called Masimo’s pulse oximetry and patient monitoring technologies “strategic fits” that will reinforce the company’s diagnostics capabilities. Pulse oximetry, widely used in acute care settings, measures blood oxygen levels, providing critical patient data.
“With the Danaher Business System and our global scale, we see opportunities to expand Masimo’s reach and continue improving outcomes for patients,” Blair said in a Tuesday statement.
